

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				Complete if Known	
Application Number		10/597,304			
Filing Date		July 19, 2006			
First Named Inventor		John P. Morseman			
Art Unit		1628			
Examiner Name		Jennifer M. Kim			
Sheet	1	of	1	Attorney Docket Number	2997-74-PUS

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	-----------------------	---	--------------------------------	--	---

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
--------------------	-----------------------	---	--------------------------------	--	--	----------------

### OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. <sup>1</sup>	Other Art
	1	COSTA, E. et al., "Dendritic spine hypoplasia and downregulation of reelin and GABAergic tone in schizophrenia vulnerability," <i>Neurobiology of Disease</i> , Blackwell Scientific Publications, Oxford, GB, Vol. 8, No. 5, Oct. 1, 2001, pp. 723-742
	2	PEET MALCOLM, "Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results," <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , Vol. 69, No. 6, Dec. 2003, pp. 477-485

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.